Artificial intelligence (AI) is fundamentally reshaping biotechnology and healthcare, unlocking the secrets hidden in complex biological data.
Machine learning in genomics and proteomics is transforming the way we detect, monitor, and treat diseases. At the heart of this revolution are innovative platforms that address some of medicine’s toughest challenges, integrating AI and molecular biology to accelerate drug development, improve diagnostics, and personalize patient care.
This wave of AI-driven biotechs not only promises to improve lives by addressing unmet medical needs, but also provides investors with a rare opportunity to support scalable, data-rich solutions, setting the stage for potentially disruptive growth in healthcare.
AI unlocks biological complexity: From data to decision-making
The challenge of interpreting vast amounts of biological data has long slowed progress in disease detection and drug discovery, and that is precisely where AI provides a valuable solution.
For example, liquid biopsies, which analyze DNA fragments circulating in the blood, are an example of the power of AI to break new ground. Unlike invasive tissue biopsies, liquid biopsies provide a minimally invasive view of the body’s molecular makeup.
But signals in the blood can be very subtle, especially in chronic conditions such as liver disease, and couldn’t be detected by older methods. Transformer-based AI models adapted to biological data can analyze millions of molecular interactions simultaneously, revealing subtle patterns and signatures missed by traditional methods, enabling early detection and personalized diagnosis, and dramatically improving outcomes.
Hepta is a liquid biopsy company developed by experts at Illumina (NASDAQ:ILMN). GRAIL, Inc. (NASDAQ:GRAL) has created an AI platform that analyzes epigenetic patterns in circulating cell-free DNA.
The company recently came out of stealth mode with $6.7 million in seed funding led by Felicis Ventures, Illumina Ventures and others. The technology is designed to replace invasive biopsies with simple blood draws and has shown strong early clinical results in detecting liver disease.
CEO Hamed Amini explained that Hepta’s platform is uniquely designed from the ground up to provide a specialized approach that sets it apart from previous AI tools used in cancer research, opening the door to new possibilities for a wide range of applications.
“I think there will be a time in the not-too-distant future when generating sufficient genomic data will no longer be a cost barrier,” he said. “Once we get there, we envision a super-comprehensive central assay that captures all epigenetic signals from a blood sample (to determine a patient’s eligibility for a particular treatment). We hope to extend this to oncology and other chronic diseases in the future.”
AI accelerates drug discovery and personalizes cancer treatment
AI is also dramatically transforming cancer treatment by accelerating drug discovery and development, and has the potential to revolutionize healthcare. Editorial in Lancet Oncology. Author Abhishek Mehta says many academic cancer centers are collaborating with private companies to use AI to optimize drug development, trials, and analysis.
For example, the cancer drug BBO-10203 was developed by researchers at Lawrence Livermore National Laboratory and Frederick National Cancer Institute in collaboration with private biotechnology company BridgeBio Oncology Therapeutics. Developers used advanced computing and AI to take it from concept to human testing in just six years. This is a significant improvement over the 10-15 year timeline of traditional drug development processes.
Other major innovators include Canadian biotech company Lacovina Therapeutics (TSXV:RKV). The company uses its AI platform, Deep Docking, and Enki to help discover drugs that target DNA damage repair processes in cancer cells.
One of its main programs is a treatment that blocks a critical protein that cancer cells need to survive. Rakovina identifies promising candidates and works with top cancer research centers to move these treatments into human trials.
AI is being deployed not only to optimize drug candidates and delivery mechanisms, but also to develop targeted therapeutic strategies.
Anand Parikh, CEO and co-founder of Faeth Therapeutics, a clinical-stage biotechnology company that uses AI to analyze a tumor’s complex metabolic dependencies and identify targets missed by traditional methods, spoke to Investing News Network about the AI analysis of cancer metabolism in the company’s DICE trial. This trial demonstrated promising ovarian cancer results by targeting the PI3K pathway from a metabolic perspective and combining drug therapy with precision nutrition.
“The next improvement in human life and survival will come from the next platform transition, and we truly believe that metabolism is metabolism. This trial will really open that door in people’s minds,” Parikh explained, adding that the complexity of metabolic function necessitates the need for machine learning. “No approach to metabolism and cancer can grow, survive, and reproduce without leveraging machine learning.”
Expanding frontiers of personalized, data-driven medicine
Going forward, AI is reshaping the drug development pipeline, with technologies such as DeepDR and SNF-CVAE expected to enhance drug discovery and repurposing and shorten clinical timelines.
For investors, the economic impact of these efficiency gains is significant: faster approvals and lower development costs can significantly increase returns while reducing risk.
AI tools will not only help drug companies select promising candidates faster and design smarter clinical trials, but also ultimately help doctors customize treatments to patients’ unique profiles, industry insiders claim.
For Faeth, the company’s AI-driven MetabOS platform narrows data related to cancer metabolism to a smaller, more manageable set of potential targets. CRISPR gene editing technology then enables further experimental validation and refinement to identify the most promising therapeutic candidates with high precision.
“There’s a patient population that really benefits,” Parikh said of the DICE trial. “So we’re going to figure out who those patients are so that doctors can get them into treatment early and get the most benefit.”
However, widespread adoption faces hurdles such as regulatory pathways and data quality standards. Still, growing investor interest and strategic partnerships show strong momentum to overcome these barriers. “If the data is good, more money will flow in,” Parikh said.
For example, Danish medical AI company Corti is gaining increasing attention for providing healthcare organizations with “AI infrastructure” designed specifically for medical use cases.
Governments are also investing heavily in AI for disease research, such as the US$500 billion Stargate project. The project includes funding earmarked for AI-powered biomedical research and infrastructure development. The UK’s £19m PharosAI initiative supports AI-powered cancer research and clinical innovation.
conclusion
AI-driven platforms are at the forefront of medical innovation.
For forward-looking investors, this is an opportunity to support innovative science while participating in a market with significant growth potential. This is not just a technology issue. It’s about changing the way we practice medicine, and ultimately how we improve and save lives.
Don’t forget to follow us @INN_technology We bring you real-time news updates!
Securities Disclosure: I, Meegen Seeter, have no direct investment interest in any companies mentioned in this article.
